Adagene to Participate in Two Upcoming Investor Conferences

Core Insights - Adagene Inc. is participating in two upcoming healthcare conferences, the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Global Healthcare Conference from March 8-11, 2026 [1][2] - The company recently presented at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, with a webcast available for viewing [3] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [4] - The company has established strategic collaborations leveraging its SAFEbody precision masking technology to address unmet patient needs in cancer treatment [4] Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, which are designed to enhance the safety and efficacy of antibody therapeutics [5] - The lead clinical program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, currently in Phase 1b/2 and Phase 2 studies targeting microsatellite stable metastatic colorectal cancer [6]